| Literature DB >> 22129478 |
Emna Abdelhamid1, Claude Preudhomme, Nathalie Helevaut, Olivier Nibourel, Claude Gardin, Philippe Rousselot, Sylvie Castaigne, Bérengère Gruson, Céline Berthon, Zohra Soua, Aline Renneville.
Abstract
FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22129478 DOI： 10.1016/j.leukres.2011.11.002
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156